YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

A Dilemma in Staging of Esophageal Cancer: How Should We Stage Ypt0 N2 M0 Esophageal Cancer After Neoadjuvant Therapy

dc.authorid Celik, Sebahattin/0000-0003-0300-0113
dc.authorid Erten, Remzi/0000-0001-7775-5792
dc.authorwosid Batur, Abdussamet/Aac-1482-2020
dc.authorwosid Erten, Remzi/V-5175-2019
dc.contributor.author Celik, Sebahattin
dc.contributor.author Erten, Remzi
dc.contributor.author Batur, Abdulsamed
dc.contributor.author Suvak, Burak
dc.date.accessioned 2025-05-10T17:42:15Z
dc.date.available 2025-05-10T17:42:15Z
dc.date.issued 2015
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Celik, Sebahattin] Yuzuncu Yil Univ, Dept Gen Surg, TR-65200 Van, Turkey; [Erten, Remzi] Yuzuncu Yil Univ, Dept Pathol, TR-65200 Van, Turkey; [Batur, Abdulsamed] Yuzuncu Yil Univ, Dept Radiol, TR-65200 Van, Turkey; [Suvak, Burak] Yuzuncu Yil Univ, Dept Gastroenterol, TR-65200 Van, Turkey en_US
dc.description Celik, Sebahattin/0000-0003-0300-0113; Erten, Remzi/0000-0001-7775-5792 en_US
dc.description.abstract Background. Since neoadjuvant treatment in esophageal cancer began to become popular, a complete pathological response at the primary tumour site has been commonly reported. An issue of conflict is whether complete response in the esophageal lumen means that the esophagus is completely tumour-free. Another important issue is whether lymph nodes that are retrieved from pathologically complete response cases are also tumour-free or not. There is a gap in the esophageal cancer staging system for ypT0 N2 M0 tumours that have received neoadjuvant therapy. Here, we will discuss the problem about staging of esophageal cancer associated with neoadjuvant therapy. Case. A female aged 40 years complaining of dysphagia was diagnosed as having locally advanced thoracic esophageal cancer. Neoadjuvant therapy decision was taken by oncology committee. Six weeks after neoadjuvant therapy, with a curative intention, minimal invasive surgery was performed. The pathology report was as follows. "There were no neoplastic cells in the suspected area of the esophageal mucosa upon examination with all staining. There was no cancer at resection margins. Four metastatic lymph nodes were infiltrated with squamous cell cancer." Conclusion. Despite the growing use of neoadjuvant treatment in locally advanced esophageal cancer in world, we do not have a protocol for the evaluation of these patients' pathology reports. We believe that new studies and new ideas are needed to resolve this dilemma associated with neoadjuvant therapy. en_US
dc.description.woscitationindex Emerging Sources Citation Index
dc.identifier.doi 10.1155/2015/158626
dc.identifier.issn 2090-6781
dc.identifier.issn 2090-679X
dc.identifier.pmid 26346409
dc.identifier.scopusquality N/A
dc.identifier.uri https://doi.org/10.1155/2015/158626
dc.identifier.uri https://hdl.handle.net/20.500.14720/15509
dc.identifier.volume 2015 en_US
dc.identifier.wos WOS:000215264200005
dc.identifier.wosquality N/A
dc.language.iso en en_US
dc.publisher Hindawi Ltd en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.title A Dilemma in Staging of Esophageal Cancer: How Should We Stage Ypt0 N2 M0 Esophageal Cancer After Neoadjuvant Therapy en_US
dc.type Article en_US

Files